文献速递产科母胎医学

常规早孕期联合筛查子痫前期的实施:一项临床有效性研究

Implementation of routine first trimester combined screening for pre-eclampsia: a clinical effectiveness study.
PubMed 文献 · BJOG · 2020-07-01

在伦敦三级医院2017年1月至2019年3月的回顾性队列研究中,7720名妇女按NICE风险指导筛查,4841名按FMF算法筛查。FMF筛查使筛查阳性率从16.1%降至8.2%(OR 0.50,95%CI 0.41-0.53),高危孕妇靶向阿司匹林使用率从28.9%升至99.0%(OR 241.6,95%CI 89.6-652.0),早产型子痫前期ROC曲线下面积0.846(95%CI 0.778-0.915,P<.001),中断时间序列分析显示早产型和早发型子痫前期相对效应分别降低80%(P=.025)和89%(P=.017)。

要点

  • FMF早孕期联合筛查使筛查阳性率从16.1%降至8.2%(OR 0.50,95%CI 0.41-0.53)。
  • 高危孕妇靶向阿司匹林使用率从28.9%升至99.0%(OR 241.6,95%CI 89.6-652.0)。
  • 早产型子痫前期筛查判别力AUC=0.846(95%CI 0.778-0.915,P<.001)。

核心结论

  • 早孕期联合筛查子痫前期在公共医疗环境中可行且有效。
  • 该方法使风险降级约两倍、子痫前期检出翻倍、医生阿司匹林使用依从性接近完全,并显著降低早产型子痫前期患病率。

研究设计与样本

  • 回顾性队列研究,地点为伦敦三级医院,时间2017年1月至2019年3月。
  • 7720名妇女按NICE风险指导筛查,4841名按FMF算法筛查,FMF算法结合母亲风险因素、血压、PAPP-A和早孕期子宫动脉多普勒指标。
  • 干预前队列高危按标准NICE标准定义并处方75 mg阿司匹林,干预后队列高危按FMF算法早产型子痫前期风险≥1:50定义并处方150 mg阿司匹林。

主要发现

  • FMF筛查使筛查阳性率从16.1%降至8.2%(OR 0.50,95%CI 0.41-0.53)。
  • 高危孕妇靶向阿司匹林使用率从28.9%升至99.0%(OR 241.6,95%CI 89.6-652.0)。
  • FMF算法筛查指标一致改善,ROC分析显示对早产型子痫前期判别力优良(AUC=0.846,95%CI 0.778-0.915,P<.001)。
  • 中断时间序列分析显示FMF筛查对早产型和早发型子痫前期分别产生80%(P=.025)和89%(P=.017)的21个月相对效应降低。

临床怎么用

  • 作者结论认为早孕期联合筛查子痫前期在公共医疗环境中可行且有效,可带来风险降级、检出翻倍、阿司匹林依从性接近完全及早产型子痫前期患病率显著降低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Evaluate clinical effectiveness of the first trimester combined (FMF) pre-eclampsia screening programme when implemented in a public healthcare setting. DESIGN: Retrospective cohort study. SETTING: London tertiary hospital from January 2017 to March 2019. METHODS: 7720 women screened for pre-eclampsia according to National Institute for Health and Care Excellence (NICE) risk-based guidance and 4841 by the Fetal Medical Foundation (FMF) algorithm which combined maternal risk factors, blood pressure, PAPP-A and uterine artery Doppler indices in the first trimester. High risk was defined by standard NICE criteria in the pre-intervention cohort (prescribed 75 mg aspirin) or a risk of ≥1:50 for preterm pre-eclampsia from the FMF algorithm in the post-intervention cohort (prescribed 150 mg aspirin). MAIN OUTCOME MEASURES: Screening effectiveness, rates of pre-eclampsia. RESULTS: The FMF screening programme resulted in a significant reduction in the screen-positive rate (16.1 versus 8.2%, odds ratio [OR] 0.50, 95% confidence interval [CI] 0.41-0.53) with a concurrent increase in targeted aspirin use in women classified as high risk for pre-eclampsia (28.9 versus 99.0%, OR 241.6, 95% CI 89.6-652.0). Screening indices were uniformly improved for the FMF algorithm with receiver operating characteristic (ROC) analysis demonstrating excellent discrimination for preterm pre-eclampsia (area under the curve [AUC] = 0.846, 95% CI 0.778-0.915, P value <.001). Interrupted time series analysis showed that the FMF screening programme resulted in a significant 21-month relative effect reduction of 80% (P = .025) and 89% (P = .017), for preterm and early pre-eclampsia, respectively. CONCLUSIONS: First trimester combined screening for pre-eclampsia is both feasible and effective in a public healthcare setting. Such an approach results in a two-fold de-escalation of risk, doubling of pre-eclampsia detection, near total physician compliance of aspirin use and a significant reduction in the prevalence of preterm pre-eclampsia. TWEETABLE ABSTRACT: Implementation of 1st trimester combined pre-eclampsia screening effectively reduces prevalence of the disorder.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Guy GP, Leslie K, Diaz Gomez D, et al. Implementation of routine first trimester combined screening for pre-eclampsia: a clinical effectiveness study. BJOG. 2020. PMID: 32613730. doi:10.1111/1471-0528.16361

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。